Aviva’s NV5 Global NVEE Stock Holding History

Aviva’s Portfolio NVEE Stock Details NVEE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-55,064	Closed	-$1.43M	–	1005
2023 Q1	$1.43M	Buy	55,064 +26,904	+96%	+$807K	0.01%	789
2022 Q4	$932K	Sell	28,160 -19,212	-41%	-$668K	﹤0.01%	901
2022 Q3	$1.47M	Sell	47,372 -22,684	-32%	-$741K	0.01%	826
2022 Q2	$2.04M	Buy	70,056 +23,400	+50%	+$702K	0.01%	797
2022 Q1	$1.55M	Buy	+46,656	New	+$1.37M	0.01%	901

Other funds holding NVEE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cercano Management Bellevue, Washington $2.32B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

Aviva's NVEE Position: Q2 2023 in Review

Aviva sold out of NV5 Global (NVEE) in Q2 2023, closing a stake of 55,064 shares — an estimated $1.43M sold.

Aviva first reported a position in NVEE in Q1 2022 and held it in 5 quarters. The position peaked at $2.04M in Q2 2022. 199 funds tracked by Wall St. Rank hold NVEE as of Q2 2023.

Aviva reported no remaining NV5 Global position as of Q2 2023 after selling out during the quarter.
Aviva sold 55,064 NV5 Global shares in Q2 2023, an estimated $1.43M.
Aviva first reported a position in NV5 Global in Q1 2022 and held it in 5 quarters.
Aviva's NV5 Global position peaked at $2.04M in Q2 2022.
199 funds tracked by Wall St. Rank held NV5 Global as of Q2 2023.

Based on Aviva's 13F filing for Q2 2023, filed 10 Aug 2023.